Form 4: TransMedics Director Thomas Gunderson Granted 2,134 Restricted Stock Units

TransMedics Group, Inc. director Thomas James Gunderson was granted 2,134 restricted stock units on May 22, 2025, increasing his beneficial ownership to 4,059 shares.

Summary

• Thomas James Gunderson, a Director of TransMedics Group, Inc. (TMDX), acquired 2,134 shares of common stock.
• The acquisition occurred on May 22, 2025, and was made pursuant to a Rule 10b5-1 plan.
• These shares are in the form of Restricted Stock Units (RSUs), where each RSU represents a contingent right to receive one share of the Issuer's common stock.
• The transaction price for these RSUs was $0, which is typical for compensation grants.
• Following this transaction, Mr. Gunderson's beneficial ownership of TransMedics Group, Inc. common stock is 4,059 shares.

Sentiment

Score: 7

Explanation: The grant of RSUs to a director is a positive sign of continued alignment between management/board and shareholders, and a standard compensation practice. It doesn't indicate any negative operational or financial news.

Positives

• The grant of Restricted Stock Units (RSUs) to a director aligns the director's interests with those of shareholders, as the value of the RSUs is tied to the company's stock performance.
• RSU grants are a common form of non-cash compensation, indicating ongoing commitment to retaining and incentivizing key personnel.

Future Outlook

This Form 4 filing is a disclosure of an insider transaction and does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This transaction is a routine insider compensation event common across all industries, where companies use equity grants like RSUs to compensate and align the interests of their directors and executives with shareholders. It does not provide specific insights into broader industry trends for medical devices or organ transplantation beyond the general practice of executive compensation.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to a director is a standard practice in corporate governance and executive compensation across various industries, including the medical technology sector.
• Companies like Medtronic (MDT), Intuitive Surgical (ISRG), and Stryker (SYK) also utilize similar equity-based compensation structures for their board members and executives to incentivize long-term performance and align interests with shareholders.
• The specific number of units granted would typically be benchmarked against peer companies of similar size and market capitalization within the medical device industry, though this document does not provide the context for such a comparison.

Stakeholder Impact

• Shareholders: The grant of RSUs aligns the director's interests with shareholders, as the value is tied to stock performance. It represents a form of potential dilution over time as RSUs vest and convert to shares, but this is a standard part of equity compensation plans.

Next Steps

• This Form 4 filing is a disclosure of a completed transaction and does not outline specific future actions or milestones for the company or the reporting person beyond the vesting schedule of the RSUs, which is not detailed in this specific filing.

Key Dates

Recommendation

Keywords

TransMedics Group Inc, TMDX, Form 4, SEC filing, Restricted Stock Units, RSU, insider transaction, director compensation, equity grant, beneficial ownership